Navigation Links
Ceregene Completes Enrollment of Phase 2 Clinical Trial for Parkinson's Disease
Date:11/14/2007

SAN DIEGO, Nov. 14 /PRNewswire-FirstCall/ -- Ceregene, Inc. today announced that the company has completed enrollment of its randomized, controlled, double-blind, Phase 2 clinical trial evaluating CERE-120, a gene therapy product in development for the treatment of Parkinson's disease. The trial enrolled 58 patients with advanced Parkinson's disease across nine medical centers in the United States. The company expects to announce results from the trial in late 2008. CERE-120 is designed to deliver the neurturin gene, a nervous system growth factor with the ability to maintain the growth and normal function of dopamine-producing neurons which deteriorate in Parkinson's disease.

The Phase 2 trial, which was supported in part by The Michael J. Fox Foundation for Parkinson's Research, was prompted by positive results from a Phase 1 study of CERE-120 which demonstrated a 36 percent (p<0.001) reduction in Parkinson's symptoms at 12 months after administration, as measured by the Unified Parkinson's Disease Rating Scale (UPDRS) motor "off" score ("motor off" meaning patients were off Parkinson's medication at evaluation time). CERE-120 was also shown to be well tolerated in the Phase 1 study. The Phase 2 study was designed to confirm these findings in a controlled trial by randomly assigning patients to receive either CERE-120 or a control treatment at a 2 to 1 ratio and is powered at 90 percent to demonstrate clinical efficacy. The patients in this Phase 2 study will be followed for 12 months for safety and efficacy.

"Completing full enrollment of this multi-center controlled trial represents an important milestone in CERE-120's development as well as in the development of Ceregene as an emerging biotechnology company," stated Jeffrey M. Ostrove, Ph.D., president and chief executive officer of Ceregene. "We are encouraged by the positive results from our Phase 1 trial and carefully designed this Phase 2 study as a controlled trial to confirm those resul
'/>"/>

SOURCE Ceregene, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Eligard(R) six-month formulation successfully completes European approval procedure
2. The ScottCare Corporation Completes Acquisition of Rozinn Electronics, a Leading Manufacturer of Cardiac Diagnostic Products
3. EaglePicher Corporation Completes Transaction to Sell EaglePicher Boron, LLC to Ceradyne, Inc. for $69 Million
4. Symmetry Medical Completes Acquisition Of Specialty Surgical Instruments
5. GSI Securitization Completes Merger and Domicile Transfer
6. Medical Services International Inc. Completes Testing for European Union (EU) Application
7. Inverness Completes Acquisition of Cholestech
8. Billians HealthDATA Completes Comprehensive Long Term Care Database Update
9. Synova Completes Sale of $3.3 Million in Senior Convertible Notes and Warrants
10. Explorer completes the map ... for the bodys blueprint
11. Labopharm completes enrolment for Phase III clinical study for its once-daily trazodone antidepressant drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/25/2014)... December 26, 2014 This is a ... the global Sterilizers industry with a focus on the ... market status of the Sterilizers manufacturers and is a ... individuals interested in the industry. This report provides a ... and manufacturing technology. In this part, the report presents ...
(Date:12/25/2014)... 26, 2014 “Every three months the trends ... A-line sweetheart evening dress will be one of the hottest ... of Yunx.co.uk says. Today, the company releases 26 A-line sweetheart ... to 80% off. , “We are trying our best ... with our latest designs. Along with affordable prices, we provide ...
(Date:12/25/2014)... 25, 2014 BambooFlooringChina.com sells many bamboo ... bamboo flooring. Today, the company announces big discounts ... styles and colors. , BambooFlooringChina.com is the world’s leader ... promotion is valid until Jan. 20, 2015. , The ... woven with a natural thread. All the bamboo strips ...
(Date:12/25/2014)... 25, 2014 (HealthDay News) -- The risk of burns ... so you need to be extra cautious, an expert ... see a significant increase in patients coming in with ... Suffolk County Volunteer Firefighters Burn Center of Stony Brook ... be full of joy, but if not careful, could ...
(Date:12/25/2014)... New York, New York (PRWEB) December 25, 2014 ... ) continue to move forward in a number ... Southern District of West Virginia, Bernstein Liebhard LLP reports. ... the Court is scheduled to convene a Joint Status ... 2015, at 10:00 a.m. Parties have been directed to ...
Breaking Medicine News(10 mins):Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 2Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 3Health News:Various Styles of Bamboo Mats in Many Colors from BambooFlooringChina.com 2Health News:Don't Let Burns Mar Your Holidays 2Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 3Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 4
... GlaxoSmithKline (NYSE: GSK ) is prepared with ... Inhalation Powder ( www.RELENZA.com ) to meet public health ... to newly updated influenza activity data ( http://www.cdc.gov/flu/weekly/ ) ... (CDC), the flu virus is widespread in 27 states. ...
... March 2 Join Jacqueline Foreman, host of Your Mental ... best-selling author John Gray whose first book Men Are ... copies worldwide. They will discuss his new book ... Men and Women Cope Differently with Stress on Thursday, ...
... March 2 /PRNewswire/ -- The Healthcare business ... the national healthcare alliance, as its preferred vendor for ... vendor designation, Thomson Reuters is authorized to sell its ... Clinical Xpert has been named the KLAS Category Leader ...
... special protein sequence, the so-called PARF motif, on their ... Singh Chhatwal and his colleague Patric Nitsche-Schmitz of the ... the role played by PARF in the development of ... a test system that is able to recognise and ...
... N.J., March 2 Managed Health Care Associates, Inc. ... announced the launch of a new website www.mhainc.com ... look more representative of MHA,s strong brand and leadership ... the latest information on MHA core businesses and supporting ...
... New CompactRIO Controller and Five FPGA-Based Chassis are Ideal ... Texas, March 2, 2009 National Instruments (Nasdaq: ... prototyping hardware that makes it possible for engineers and ... time to market and lower development costs. The five ...
Cached Medicine News:Health News:Ample Supplies of Relenza Available as Flu Season Peaks 2Health News:Ample Supplies of Relenza Available as Flu Season Peaks 3Health News:John Gray Will Discuss His New Book Why Mars and Venus Collide 2Health News:VHA Selects Clinical Xpert from Thomson Reuters as its Preferred Solution for Mobile Clinical Improvement Systems 2Health News:VHA Selects Clinical Xpert from Thomson Reuters as its Preferred Solution for Mobile Clinical Improvement Systems 3Health News:Help for children with sick hearts 2Health News:MHA Announces: Launch of New Website 2Health News:National Instruments Announces New Suite of Prototyping Hardware to Lower Development Time and Costs 2Health News:National Instruments Announces New Suite of Prototyping Hardware to Lower Development Time and Costs 3Health News:National Instruments Announces New Suite of Prototyping Hardware to Lower Development Time and Costs 4
(Date:12/24/2014)... 24, 2014  The International Trade Commission (ITC) issued its ... BMC Medical. In a notice issued on December 23, the ... patent on its humidifier was invalid. BMC President, ... "We are very excited with the ITC,s decision in this ... have taken since the very beginning on the key patents ...
(Date:12/24/2014)... and FARMINGTON, Conn. ... Inc. (NYSE MKT: PTN), a biopharmaceutical company developing ... diseases with significant unmet medical need and commercial ... a private placement of 2,050,000 shares of its ... 24,949,325 shares of its common stock.  Funds under ...
(Date:12/24/2014)... 2014 Echo Therapeutics, Inc. (NASDAQ: ... on skin permeation, continuous glucose monitoring and associated ... has been appointed Chief Executive Officer effective ... 20 years of experience in the medical device, ... served as Vice President, Business Development, Otsuka Pharmaceuticals as ...
Breaking Medicine Technology:ITC Final Decision Goes Against ResMed (RMD) Monumental Win for 3B/BMC 2Palatin Completes $20 Million Equity and $10 Million Debt Financings 2Palatin Completes $20 Million Equity and $10 Million Debt Financings 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 4Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 2Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 3
LOGIQ Book XP provides you the next generation performance in a compact platform....
The Rio Catheter is designed to simplify your intravascular interventions by removing thrombus and restoring epicardial flow to the procedure....
... Guidant VASOVIEW® HemoPro™ EVH system ... new level of performance in ... the saphenous vein and radial ... it lets you make a ...
Patient Monitor...
Medicine Products: